Content area
Full text
The FDA recently announced approval of a once-daily, fixed-dose combination therapy containing sitagliptin and simvastatin for the treatment of adults with type 2 diabetes and high cholesterol.
"This is the first product to combine a type 2 diabetes drug with a cholesterollowering drug in one tablet," Mary H. Park, MD, director of the division of metabolism and endocrinology products in the FDA Center for Drug Evaluation and Research, said in a press release. "However, to ensure safe and effective use...